Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.

Published in: British journal of haematology (2024)

Anti-PD1-based first-line treatment holds great promise in classical Hodgkin lymphoma. The management of immune-related adverse events in the context of time-limited combined checkpoint blockade and chemotherapy administered in curative intent is a challenge. Kuczmarski and Lynch provide a case-based approach to key toxicities observed in this setting. Commentary on: Kuczmarski et al. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19478.

Keyphrases

hodgkin lymphoma
dna damage
cell cycle
locally advanced
social media
health information
big data
oxidative stress
machine learning
chemotherapy induced
artificial intelligence
drug induced